Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..

In a nationwide sample of Black women in the U.S., we assessed preferences for HIV preexposure prophylaxis (PrEP) products, including long-acting injectable (LAI) PrEP and once-daily oral PrEP. Among 315 respondents, 32.1% were aware of PrEP and 40.6% were interested in using it; interest increased to 62.2% if PrEP were provided for free. Oral PrEP was the preferred option (51.1%), followed by LAI PrEP (25.7%), vaginal gel (16.5%), and vaginal ring (6.7%). When examining oral and LAI PrEP alone, most (62.7%) preferred oral PrEP. LAI PrEP was more likely to be preferred among respondents with concerns about healthcare costs or PrEP-related stigma, and among those who reported inconsistent condom use and multiple sexual partners. Although most Black women preferred oral PrEP, LAI PrEP may be appealing to a subset with social and structural barriers to PrEP use, such as cost and stigma, and those at increased risk of HIV infection.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:26

Enthalten in:

AIDS and behavior - 26(2022), 7 vom: 05. Juli, Seite 2212-2223

Sprache:

Englisch

Beteiligte Personen:

Irie, Whitney C [VerfasserIn]
Calabrese, Sarah K [VerfasserIn]
Patel, Rupa R [VerfasserIn]
Mayer, Kenneth H [VerfasserIn]
Geng, Elvin H [VerfasserIn]
Marcus, Julia L [VerfasserIn]

Links:

Volltext

Themen:

Anti-HIV Agents
Black women
Cabotegravir
HIV prevention
Journal Article
Long-acting injectable (LAI)
Preexposure prophylaxis (PrEP)

Anmerkungen:

Date Completed 06.06.2022

Date Revised 12.09.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1007/s10461-021-03571-8

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM33521004X